
News
BioLife Solutions and STEMCELL Technologies Announce Worldwide Distribution Agreement

News
BioLife Solutions and STEMCELL Technologies Announce Worldwide Distribution Agreement
Read time:
Want a FREE PDF version of This News Story?
Complete the form below and we will email you a PDF version of "BioLife Solutions and STEMCELL Technologies Announce Worldwide Distribution Agreement"
First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?
BioLife Solutions, Inc. has announced that it has entered into a non-exclusive distribution agreement with STEMCELL Technologies, Inc., based in Vancouver, Canada.
Mike Rice, BioLife's chairman and CEO, noted, "We're very pleased to now have our products represented and distributed throughout the world by STEMCELL Technologies and their sub-distributor partners. Their MethoCult reagent systems have become worldwide standards and we look forward to their distribution network's ability to help our HypoThermosol and CryoStor product platforms achieve the same level of product adoption."
Allen Eaves M.D., Ph.D., founder of STEMCELL Technologies and Chairman of the StemCell Group, commented on the addition of BioLife's products to their reagents and media portfolio by stating, "Our interest in BioLife Solutions has grown as we've seen their products adopted by numerous customers in our strategic markets. We also conducted several comparative cell preservation experiments with CryoStor against other freeze media and were very impressed by the performance of CryoStor in improving post-thaw cell viability and recovery. We feel that the robust regulatory and quality footprint of serum-free and protein-free CryoStor and HypoThermosol will increasingly be valued by researchers and clinicians around the world."
Mike Rice, BioLife's chairman and CEO, noted, "We're very pleased to now have our products represented and distributed throughout the world by STEMCELL Technologies and their sub-distributor partners. Their MethoCult reagent systems have become worldwide standards and we look forward to their distribution network's ability to help our HypoThermosol and CryoStor product platforms achieve the same level of product adoption."
Allen Eaves M.D., Ph.D., founder of STEMCELL Technologies and Chairman of the StemCell Group, commented on the addition of BioLife's products to their reagents and media portfolio by stating, "Our interest in BioLife Solutions has grown as we've seen their products adopted by numerous customers in our strategic markets. We also conducted several comparative cell preservation experiments with CryoStor against other freeze media and were very impressed by the performance of CryoStor in improving post-thaw cell viability and recovery. We feel that the robust regulatory and quality footprint of serum-free and protein-free CryoStor and HypoThermosol will increasingly be valued by researchers and clinicians around the world."
Advertisement